Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

Manuscript Number: 

15-0376R1

Author(s): 
Nick C. Fox, Ann Holstein, Nicholas Jackson, Nzeera Ketter, Ghislaine Le Prince Leterme, Enchi Liu, Florence Pasquier, Yahong Peng, J. Michael Ryan, Carl Sadowsky

Disclosures

Nick C. Fox

  • Consulting Fees:
    N Fox declares that image analyses of MRI scans in this study were performed at the Dementia Research Centre and UCL Institute of Neurology received payments under contract for this work from Pfizer Inc.; UCL Institute of Neurology also received payment for image analyses from Janssen Alzheimer Immunotherapy. NF provided consultancy services, under UCL Institute of Neurology, for Eli Lilly, GSK, Novartis, Roche and Sanofi outside the submitted work.

Ann Holstein

  • Nothing to Disclose

Nicholas Jackson

  • Sponsors:
    I was previously employed by the sponsor of the study, and stopped by employment in 2013

Nzeera Ketter

  • Equity:
    Johnson & Johnson
    Sponsors:
    Johnson & Johnson

Ghislaine Le Prince Leterme

  • Equity:
    currently owns stock in the company
    Sponsors:
    currently a Pfizer employee and was during the conduct of the studies

Enchi Liu

  • Sponsors:
    I was an employee of Janssen Alzheimer Immunotherapy from 2009-2013 and an employee of Janssen R&D from 2013-2015 during which time the study was conducted, the data interpretation was performed, and manuscript generation/finalization was completed.

Florence Pasquier

  • Consulting Fees:
    F. Pasquier declares that CHRU de Lille and Adrinord received payment for her participation as principal investigator for the present trial as well as clinical trials for Exonhit, Janssen, Lilly, Noscira, Pharnex, Bayer, Piramel, Roche, BMS, GE Healthcare, Envivo, Piramal and Sanofi outside the submitted work. FP also declares receiving payment for participation in advisory boards for Ethypharm and Nutricia outside the submitted work.

Yahong Peng

  • Equity:
    I own Pfizer stocks.
    Sponsors:
    I am a Pfizer employee.

J. Michael Ryan

  • Equity:
    J. M. Ryan has previously owned stock of Pfizer Inc and currently owns Novartis stock
    Sponsors:
    J. M. Ryan was an employee of Pfizer Inc at the time the study was conducted

Carl Sadowsky

  • Consulting Fees:
    Cognoptix, Lilly
    Lecture Fees:
    Lilly